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Thank you for submitting your manuscript for consideration by the EMBO Journal. Please let me first apologise for the slight delay in getting back to you with a decision; unfortunately there was a delay in receiving the final referee's report. However, we do now have the comments of all three referees, which are enclosed below. As you will see, both referees 1 and 2 express interest in the work, and are broadly in favour of publication -pending major revision as detailed below. Referee 3, on the other hand, is rather negative about the study, finding the conceptual advance to be limited. We do recognise that his/her report is rather dismissive, and given the more positive opinions of the majority of reviewers, we are willing to over-rule his/her recommendation. However, it is clear that a significant amount of work would be required in order for your manuscript to be potentially suitable for publication in the EMBO Journal.
Most critically, both referees 1 and 2 comment that you do not test whether any of the novel GLD-1 targets are genuinely regulated in vivo, or show that this regulation represents a direct repression of translation by GLD-1. Substantial data on this point would be essential in any revised version of the manuscript. Secondly, both referees comment on various aspects of the computational analysis of the data, particularly in terms of how your 7-mer GBM differs from the previously identified SBE, as well as whether the classification of GBMs into strong, medium and weak motifs is genuinely justified. A third major issue, highlighted by referee 1 in point 4, concerns the question as to the importance of RNA structure for GLD-1 regulation. The referee's suggestion that you analyse GBMs in unfavourable secondary structure contexts would clearly be very valuable here. One final point, mentioned by both referees in their comments to the editor, regards the title, which both reviewers find to be unsupported by the data, and which needs to be more cautiously phrased.
Given the positive recommendations of referees 1 and 2, I would like to invite you to submit a revised version of the manuscript, addressing particularly the comments above, but also responding to the other issues raised by the reviewers. I should add that it is EMBO Journal policy to allow only a single round of revision. Acceptance of your manuscript will thus depend on the completeness of your responses included in the next, final version of the manuscript. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as a standard revision time, and as a matter of policy, we do not consider any competing manuscripts published during this period as negatively impacting on the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely,
Editor
The EMBO Journal
REFEREE REPORTS
Referee #1 (Remarks to the Author):
"An RNA code, based on number and strength of 7-mer motifs, determines mRNA regulation by the germ line fate determinant GLD-1".
This manuscript is centered on an in vivo RIP-chip (i.e. pulldown/microarray) experiment in C. elegans, with young adult worms expressing a FLAG/GFP tagged GLD-1 transgene. The pulldown identified 948 enriched RNAs using a cutoff of 3-fold, and by various criteria the array data were found to be reproducible.
Examination of the 3' UTRs of these genes identified 32 enriched 6mers, each of which is partially overlapping with a subset of the other 6mers. The appearance of these 6mers in UTRs correlates with IP enrichment. Motif searching with MEME suggested a 7-base binding site. A regression model was created that sums contributions from 80 individual top-scoring 7-mers. The coefficients obtained correlate with the MEME score for the same 7-mers. The 7-mer model also correlates with IP enrichment when scored on UTRs, but not coding sequence, arguing that sites in the ORF are not utilized. Overall, the 7-mer model scored on UTRs has a correlation of 0.64 with the IP enrichment.
There is also quite a bit of discussion about strong, medium, and weak binding 7-mers, but to me these arguments serve mainly to make Figure 3C which has a better correlation than 0.64., Of course, any transformation of Figure 3E that averages over bins will yield a higher correlation. The bins are also used for some of the follow-up analysis, but they aren't really required for that; the figures give a discrete score.
There is also a brief section on GO enrichment and anti-targets.
To illustrate that the GLD-1 Binding Motifs (GBMs) contribute to gene regulation, a series of mutant constructs are analyzed in which artificial UTRs are shown to bind or not bind GLD-1, and to regulate (or not) expression of GFP fusions in vivo.
There are also two sections at the end claiming that a permissive RNA structure is required for GLD-1 recognition, and that the strength of a GBM is relevant to translation. I find these sections unconvincing (see below).
Overall the paper provides a nice initial data set. The results of the follow-up studies are all consistent and convincing. I'm sure this paper will be of interest not only to investigators interested in GLD-1, but that it will also become a solid example of successfully connecting an RNA-binding protein to its sequence specificity and demonstrating the importance of the relevant elements.
That said, many of the claims are overstated, given the data presented -including the relevance of the 7-mers vs. the motif model, the RNA structural context, and the impact on translation. In addition, the paper is a difficult read in its current form and would benefit from some reorganization.
Major points:
(1) The paper (including the title) focuses on the 7-mer model. However, there really is no evidence presented that the 7-mer model is better than the motif model. In fact, it is stated that they correlate highly, indicating that positional dependences play a minor role. So, introducing the 7-mer model is just making things more complicated. The motif model is more compact and can also be used to either quantitatively score binding sites, or to put them into bins. It is also widely understood. If the paper is going to deviate from the standard (and simpler) way of representing the RNA-binding activity, there should be a demonstration that it is significantly superior. Such a demonstration should also make use of more advanced tools than MEME. For example, if the goal is to quantitatively score sequences, then something like MatrixREDUCE might be more appropriate. In addition, training and testing motif models (including the 7-mer model) should ideally involve some form of cross-validation to avoid circularity.
On the same topic, running the reader through the 6-mer counts, then the motif searching, then the 7-mer model, then the comparisons and binning etc, is really a lot to go through just to come to the conclusion that a motif has been identified. The paper would be much easier to follow if it just stated that it is possible to find a motif that explains the data, and that enumeration of k-mers doesn't help much, if at all.
(2)
The description of the RNA pulldown assays in vitro is either insufficient or absent. I'm going to assume that these are oligo pulldowns or something of that sort. Is this the biotin-RNA pulldown assay briefly alluded to in the Methods? The reader shouldn't have to go read other papers just to get an idea of what kind of experiment is being done. Overall, I don't find the protein pulldown experiments very convincing. In Figure 4B , why do all the mutants have such a strong band? If these sites are really that important, why does a substantial fraction of the protein come down if the GBM score is zero, relative to an RNA with a GBM score near 1? The same seems to be true in Figure 4E and 6B. Using words like "prevented GLD-1 binding" seems a bit exaggerated. I understand that there is a relationship here between the strength of the band and the GBM score, but let's not overstate it.
(3)
There needs to be a better comparison between the GBM and the previously-identified SBE. Including a correlation between SBE scores and pulldown scores. It would also be helpful to have a figure showing what all of these motifs and consensus sequences look like. It's also not clear whether M2 also scores as a GBM.
(4)
The RNA structure analysis really has too few examples to draw any sort of conclusion. The statement at the end that "We observed little increase in predictive power (data not shown) suggesting that the majority of GBMs reside in favorable structural environments" however is testable -do they? I would posit that they do not and that this conclusion is erroneous unless it is demonstrated that the majority of GBMs do reside in favourable structural environments. A more direct way to show that GLD-1 requires a single-stranded binding site would be to show that those GBMs in unfavourable contexts are associated with low IP (or negative) IP enrichment. There is a body of recent literature on this type of analysis that would be worth looking into, e.g. in PLoS Computational Biology, RNA, etc. there have been a series of such investigations which should be acknowledged and (hopefully) followed.
The correlation in 3E seems inflated by the choice of the Pearson correlation coefficient which here is inappropriate, Spearman would be a better choice. In particular, the single point in the top right corner is the likely cause of the relatively high correlation. When I look at this scatterplot, I see three regions defined by the IP enrichment: 0-2, 3-6, and >7 and within those regions there's very little correlation between IP enrichment and predicted binding score. If so, this means that at best, it seems that predicted binding score can group the transcripts into three classes, one of which only contains a single point. (6) Related to the previous point, there's no description that I could find on how the thresholds for strong, medium and weak were chosen. These divisions (especially those between medium and weak) seems arbitrary. It should also be reported how "predicted binding score / category" was determined in 3C. (7) Throughout the manuscript, it is reported that multiple GBMs make additive contributions to the measured binding of GLD-1. However, that's not strictly true because, as the manuscript points out, they are additive in log space which means that the contributions are actually multiplicative.
(8)
In the last section of the results it is shown that a strong GBM results in an increase in repression. However, how does this show that the strength of the GBM is relevant for translational regulation, vs. transcript stability? Isn't it possible that there are fewer transcripts and that each of them is translated at the same rate? (9) To me, the sections "Validation of GBMs", "GBMs are predictive for GLD-1 mediated regulation", "A GBM is sufficient to induce GLD-1 mediated regulation", and "The strength of a GBM is relevant for translational regulation in vivo" are all just different varieties of demonstrating that GBMs are necessary and sufficient for regulation. In fact, Figures 4, 5, 6 , and 7 all have the same format. It would be much easier for the reader if these were simply grouped into a section with a title something like "GBMs are necessary and sufficient for quantitative repression". As noted above I don't see any direct evidence for translational regulation so I think that can't be included.
In addition, I don't see any evidence that GLD-1 is required for repression, since there are no experiments in gld-1 mutants, which would be necessary to provide this evidence. Instead, what is shown is that these sites can pull down GLD-1 protein in vitro, and that they confer regulation. However, they do not rule out the possibility that some other protein is binding the GLD-1 site and doing the regulating.
(10) I would also point out that there is no direct demonstration that GLD-1 binds to the short sequence motifs identified -the evidence is all based on mutation of larger RNAs. I don't see this as a fatal flaw but certainly some of the conclusions might be tempered by this fact, and in my view the title should be modified to reflect only what is solidly and directly supported by the data in the paper.
(11) Finally, it isn't clear if the full sequences of the various constructs are posted anywhere, but it would be very useful for future investigators to have them, in order to confirm and re-analyze the data, in particular any claims about RNA structure context. They should be included in the Supplementary data. Referee #2 (Remarks to the Author):
The GLD-1 RNA-binding protein regulates meiotic progression in the C. elegans germline. The authors use immunoprecipitation of a tagged GDL-1 protein to identify 948 potential mRNA targets of GLD-1. Analysis of the candidates 3' UTR sequences reveals a degenerate GLD-1 binding motif (GBM), that is closely related, although not identical, to the GLD-1 binding site defined in vitro by another group (Ryder et al., 2003) . The authors define an algorithm to determine the relative strength of each GBM and show that this algorithm can predict both 1) GLD-1 binding strength in worm extracts and 2) regulation by GLD-1 in vivo in the context of 3 known gld-1 mRNA targets and of one artifical 3'UTR where GBM of different strengths have been transplanted. This work stands out as a remarkable demonstration that binding sites for an RNA binding protein 1) can be determined by analyzing 3' UTR sequences of co-precipitated mRNAs and 2) can be used to predict functional motifs in the UTRs of previously defined GLD1 targets. The only question not addressed by this study is whether the GBM algorithm is in fact sufficient to identify new GLD-1 targets. Some of the new candidates have known protein distributions, are these consistent with GLD-1 regulation?? The authors seem to equate GLD-1 binding in extracts with GLD-1 regulation in vivo, but the two may not always correlate? Specifically, I recommend the authors address the following.
1.The authors suggest on page 5 that the IP is specific and reflects endogenous targets because the "IP is significantly enriched for germline expressed mRNAs relative to input (data not shown)". The authors should show these data and demonstrate that high abundance somatic transcripts that contain GBMs were not immunoprecipitated.
2. Fig. 3C shows that there is an excellent correlation between predicted binding score and enrichment in the GLD-1 IP, when comparing IP averages for array-detected mRNAs grouped by binding score. Fig. 3E , however, shows that the correlation does not hold as well when all germline expressed mRNAs are examined one by one. Most surprisingly, it appears that many mRNAs with low predicted binding scores nevertheless show significant IP values. Can the authors explain this discrepancy?? Does this mean that there are other GLD-1 binding sites? The authors state that "the predictor scores are a good reflection of actual GLD-1 mRNA interactions" when in fact the R value indicates that the behavior of nearly 40% of all germline mRNAs cannot be predicted based on the score.
3. The authors state that "the GBM is distinct from the previously reported SBE", without showing a comparison. The SBE (UACUCA) is in fact a more stringent and shorter GBM??? If SBEs are used instead of GBMs in the analysis presented in Fig. 3E , what would be the R value?
4. In their analysis of the GLP-1 3' UTR (Fig. 4) , the authors claim that GBMs, not SBEs, are responsible for regulation. In fact, the critical element identified by the mutation analysis matches both a GBM and an SBE (GBM3/SBE1). Is it possible that both types of elements are functional??
5. Sup Fig. 1 lists all mRNAs identified by the array but does not highlight the "948 reproducibly identified mRNAs (page 5)". It would be very helpful if this list were modified to also include gene names and predicted GBM scores (included only in the second list). The list should also highlight the new 948 high confidence GLD-1 targets identified by this study, as well as the previously identified GLD-1 targets.
6. Among the 948 targets, how many have known protein distribution?? Are those consistent with GLD-1 regulation??? For example, the top 2 ranked gene are OMA-2 and EGG-1, whose protein distribution are known?? Ideally this information would also be included in the Sup. Fig. 1 list. 7. T23G11.3 was very highly enriched in the IP (13th most enriched). This gene codes for GLD-1 itself, is GLD-1 expected to autoregulate?? Referee #3 (Remarks to the Author):
Wright et al use a RIP approach followed by microarray analysis to identify GLD-1 mRNA targets using myc and flag tagged GLD-1 in transgenic worms. With a cut off of 3-fold they identified 948 mRNA targets that are common to both IPs. They use a bioinformatic approach to search for sequences enriched in GLD-1 targets and identify a 7-mer (GBM) that they labelled as strong, medium, weak or no affinity for GLD-1. The GBM (contains variations of UACUAAC, CACUAAC Table 1 ) that closely resembles the QKI/GLDi consensus sequence identified previously by Ryder et al., NSMB 11: 20-28 (2004) and Galarneau and Richard NSMB 12:691-698 (2005) . The authors perform a binding assay in vitro with biotinylated RNA and also generate transgenic worms with GFP::H2B reporter containing various 3'UTR to validate the 7-mer binding sites in GLD-1 targets.
Overall this manuscript confirms that STAR family of RBPs of the QR binds an element within the 3'UTR of mRNAs with a sequence variation of UACUAAC or CACUAAC and adds little new information about GLD-1 function or mechanism of action. It is more suitable for a specialized journal.
Other comments 1. The RIP is likely to identify RNA targets for GLD-1 coIP RNA binding proteins and some may be germline specific. The fact that elevated amount of RNA targets from the germline versus input were obtained does not necessarily mean they are indeed GLD-1 targets.
2. The binding assays performed in figures 4 and 7 measure relative affinities. To provide proof of the various degrees of affinities of the GBMs binding curves should be performed and affinity constants obtained.
Additional Correspondence 07 July 2010
Many thanks for your decision and comments. We think we will be able to address most points raised by both reviewers. I would like however to clarify some issues to avoid future misunderstanding.
(1) We are advised to substantially enlarge on novel targets and a direct translational repression.
The reviewer 1 (but not 2) would like to see proof of 'direct translational repression". We will certainly try as suggested to (A) quantify RNA levels to exclude e-stabilization and (B) cross the reporters into the gld-1 mutant. However, a more 'direct' proof would require an in vitro mRNA translation model that does not exist for the worm and we are hoping this is not expected from us.
Reviewer 2 (but not 1) wonders about novel targets. He/she suggests literature mining to see if available expression patterns correlate with GLD-1 regulation. This we can certainly do. However testing novel targets directly (which he/she does not seem to demand) will be time-consuming. All reporters need to be integrated (transient transfections are silenced in the germ line), which takes a lot of time. I imagine we can try to (C) verify a small set of novel UTRs for GLD-1 regulation with the GFP reporter..
We think approaches A-C are possible and should address reviewers' concerns, but we would be very grateful for your opinion as to whether they would also address your concerns.
(2) Do we need to respond to the comments from reviewer 3?
(3) We will of course try to send a revised version by the deadline, but considering the nature of some experiments (C) a delay is quite possible. If we realize that it may be difficult to stay within the deadline I will contact you immediately.
All of the other points are clear. Thank you for your time and help in clarifying the above issues.
Additional Correspondence 08 July 2010
Many thanks for your message about the revision of your manuscript -it's certainly helpful to discuss these things up front at the beginning of the revision process, so I'm very glad you got in touch!
Taking each of your points in turn:
Certainly we would not expect you to develop an in vitro mRNA translation assay, and the two approaches you outline seem perfectly sufficient to me -if you can show that the RNA is not destabilised, but that protein levels (or reporter levels if you do not have appropriate antibodies) are reduced, this should be conclusive enough.
As for the question as to novel targets, referee 2 actually states this rather strongly in his/her confidential comments to the editor, and I'm sorry to say that I had not realised it was not stated explicitly in the remarks to the authors. His/her point is that the only targets you test in vivo are known GLD-1 targets. I agree with the referee that it would be very valuable to show that at least a few of the novel targets are indeed regulated by GLD-1 in vivo. Of course, the ideal thing here would be to show that a target with a low score is only weakly regulated by GLD-1 (or only in the region of the gonad where GLD-1 is most strongly expressed), whereas a high scoring target is more strongly regulated. I recognise, however, that this might be rather difficult given the technical considerations. I think that your suggestion to test a few using reporter assays (or using any available antibodies for potential targets) would be sufficient here -although obviously this would have to be approved by the referee upon submission of the revised version. Should you need longer than the normal 3-month revision time to accomplish this, we should be able to accommodate an extension: please just let me know nearer the deadline if you need more time.
Referee 3's major specific criticism concerns the determination of affinity constants. Clearly, if you are able to do this, it would strengthen your model, so I would encourage you to attempt these experiments. However, I would not see this as being essential for eventual publication. As for his/her point 1, I think the point being made is that it is possible that other RNA-binding proteins coIP-ing with GLD-1 could be the factors actually binding the targets. Of course, this is a possibility, but given that you have already done and will be doing substantial validation, I wouldn't worry too much about this; any study of this kind would have similar caveats! I hope these comments are helpful, and please don't hesitate to get in touch if you have further questions. Otherwise, I look forward to receiving your revision. Figure 6 ) and in every case confirmed that the 3'UTR containing the wild type GBM was sufficient to mediate an expression pattern complementary to GLD-1, suggesting that it is regulated by GLD-1 in vivo. Furthermore, in every case, mutating the GBM caused de-repression of GFP expression in the medial gonad ñ the region where GLD-1 is expressed. We additionally showed for some reporters which have a weak, strong or mutated GBM that GFP transcript levels are similar (by RT-QPCR and in situ hybridization), suggesting that differences observed in protein expression likely represent repression of translation ( Figure 7 & data not shown).
Secondly, both referees comment on various aspects of the computational analysis of the data, particularly in terms of how your 7-mer GBM differs from the previously identified SBE, as well as whether the classification of GBMs into strong, medium and weak motifs is genuinely justified.
> We now included a detailed comparison of GBM and SBE (see Figure for Reviewers 1, Table S2 ). Supplementary Table S2 indicates the GBMs that are distinct from the SBE criteria. Figure for reviewers 1 shows the poor correlation between SBE and GBM scores. Motifs which would be identified as only GBMs, only SBEs or as both motifs are easily identifiable in this figure.
Furthermore, relative affinities of all GBMs have now been determined in vitro, in an approach similar to that originally used to determine the SBE. These scores correlate well with the GBM scores derived from analysis of IP enrichment ( Figure 4B ). The classification of GBMs into strong, medium and weak motifs was driven by visual inspection (the strong sites were clearly separated from the rest) and the cut-offs were arbitrarily chosen.
A third major issue, highlighted by referee 1 in point 4, concerns the question as to the importance of RNA structure for GLD-1 regulation. The referee's suggestion that you analyse GBMs in
unfavourable secondary structure contexts would clearly be very valuable here. > From our experiment on the rme-2 3' UTR, in which a GBM is engineered to be present within a dsRNA secondary structure, it is clear that context can be important for GLD-1 binding and regulation. We have now also included results from a genome wide analysis of secondary structure ( Supplementary Fig. S5 ). We found that GBMs within potentially unfavorable context are associated with lower IP enrichment. However, the predicted contribution to GLD-1 binding is minor as compared to the presence of the actual motif. This can be due to a number of reasons including imperfect structure prediction. Thus, although the general trend observed from the global analysis agrees with the tested example (rme-2), structure prediction would add little to our GLD-1 binding predictor.
One final point, mentioned by both referees in their comments to the editor, regards the title, which both reviewers find to be unsupported by the data, and which needs to be more cautiously phrased. >We have changed the title and think it now fits well with the data shown in the manuscript.
( 1) Figure 3B is not perfect (0.8). We believe that this discrepancy is caused mainly by the following two issues: The weight matrix score (x-axis) is not perfect because MEME has never ëseen' the actual IP enrichments and was therefore not able to adjust to that. Secondly, the linear regression (y-axis) certainly suffers from overfitting caused by the extensive freedom of scoring individual 7-mers. Therefore, we decided, to use the mean of both readouts as our best guess (reducing overfitting but also taking into account IP enrichment). We think departure from this strategy would require a motif-search tool that takes the IP enrichment directly into account during weight matrix inference. In this context we tested MatrixREDUCE. We used it to infer a position-specific affinity matrix (PSAM) from the same data. Indeed, it found a degenerate PSAM with high similarity to the weight matrix inferred by MEME (see reviewers Figure 2 ). The overall accuracy for all the genes (not only germline expressed ones) was r=0.49 compared to 0.51 from our method (both comparisons done in log space). So the overall accuracy is very comparable. We then went on to recreate the target multiplicity Figure 3c (categorizing transcripts according to the number of strong, medium and weak sites) by replacing the MEME weight matrix by the PSAM computed by MatrixREDUCE (see Figure for Reviewers 3). The predicted enrichment of MatrixREDUCE is in absolute space so we therefore log transformed afterwards to make the figure comparable (see axes labels). Surprisingly, we no longer see a perfect diagonal but a clear bending. We tried to nail down the reason for this but we could not get a definitive answer. One substantial difference between MatrixREDUCE and our approach is the space in which they operate. MatrixREDUCE assumes additive contributions of sites while assuming multiplicative contributions for individual positions within the site. The fit is performed in absolute space (see eq. 9 in bioinformatics paper PMID: 16873464). Our linear regression assumes multiplicative contribution of sites and multiplicative contributions for positions within the site; the fit is performed in log space.
As pointed out by the reviewer, there is potential circularity in our analysis. We use a linear regression model in log space (which assumes multiplicative contributions) to show that the contributions of multiple sites are multiplicative. To exclude this possibility, we performed a 10 fold cross validation. In each round, we used 90% of the genes to infer the 7mer scores and subsequently categorized the remaining 10% to produce the target site multiplicity figure (included in the manuscript, see there for details ñ Supplementary Figure S3 ). Cross validation had no influence on the outcome. Taken together, we think that our previous strategy was the right one. Our method revealed a perfect diagonal for multiplicity which required fewer assumptions than the outcome of MatrixREDUCE.
Cross validation showed that we did not impose perfect multiplicity on the data but that this is rather a feature of the data.
On the same topic, running the reader through the 6-mer counts, then the motif searching, then the 7-mer model, then the comparisons and binning etc, is really a lot to go through just to come to the conclusion that a motif has been identified. The paper would be much easier to follow if it just stated that it is possible to find a motif that explains the data, and that enumeration of k-mers doesn't help much, if at all. >We agree that this is partially redundant. But the benefit of the 6mer analysis is that it provides a raw picture of the data without going through a black box tool like MEME. It provides solid evidence that the motif is degenerate, that there is predominantly only one motif and that motif enrichment correlates with IP enrichment in a quantitative fashion. These statements would be hard to make based on the MEME output. Nevertheless we went through the text and made this section more concise.
(2) The description of the RNA pulldown assays in vitro is either insufficient or absent. I'm going to assume that these are oligo pulldowns or something of that sort. Is this the biotin-RNA pulldown assay briefly alluded to in the Methods? The reader shouldn't have to go read other papers just to get an idea of what kind of experiment is being done. Overall, I don't find the protein pull-down experiments very convincing. In Figure 4B, why do all the mutants have such a strong band? If these sites are really that important, why does a substantial fraction of the protein come down if the GBM score is zero, relative to an RNA with a GBM score near 1? The same seems to be true in Figure 4E and 6B. Using words like "prevented GLD-1 binding" seems a bit exaggerated. I understand that there is a relationship here between the strength of the band and the GBM score, but let's not overstate it.
>The RNA pulldown assay in vitro is indeed the same assay as the biotin-RNA pulldown assay described in the methods. We have now labeled this as such in the relevant legend ( Figure 5 ). The method is described in several recent papers ñ we reference them but do not think it is necessary to describe it again here. The mutants in Figure 4B (now Figure 5A ) have a clearly visible band ñ however this is comparable to the band observed in the antisense lane. The antisense RNA is used as a control to establish the background in the assay. In this respect the reviewer is correct to point out that to say "prevented GLD-1 binding" is a bit exaggerated. Reduced binding to background levels is more appropriate. We agree with the referee that the main and only point we wanted to make from this assay is that there appears to be a correlation between the cumulative GBM strength of an RNA and the strength of the band observed. We have tried to re-write these sections of the manuscript to more accurately reflect what is shown in Figure 5 .
(3) There needs to be a better comparison between the GBM and the previously-identified SBE. Including a correlation between SBE scores and pulldown scores. It would also be helpful to have a figure showing what all of these motifs and consensus sequences look like. It's also not clear whether M2 also scores as a GBM.
> We now included a detailed comparison of GBM and SBE (see Figure for Reviewers 1, Table S2 ). Supplementary Table S2 indicates the GBMs that are distinct from the SBE criteria. Figure for reviewers 1 shows the poor correlation between SBE and GBM scores and from this figure it is easy to identify the motifs predicted by only one or both predictions. Furthermore, relative affinities of all GBMs have now been determined in vitro, in an approach similar to that originally used to determine the SBE. These scores correlate well with the GBM scores derived from analysis of IP enrichment ( Figure 4B) . To show what all of these motifs look like - Table 1 indicates all 80 7-mers indicated in Figure 3B highlighting the 38 GBMs. Additionally Supplementary Table S2 indicates those GBMs tested in reporter assays. The M2 sequence scores neither as GBM nor SBE and its actual sequence is given in Supplementary Table S6 .
(4) The RNA structure analysis really has too few examples to draw any sort of conclusion. The statement at the end that "We observed little increase in predictive power (data not shown) suggesting that the majority of GBMs reside in favorable structural environments" however is testable -do they? I would posit that they do not and that this conclusion is erroneous unless it is demonstrated that the majority of GBMs do reside in favourable structural environments. A more direct way to show that GLD-1 requires a single-stranded binding site would be to show that those GBMs in unfavourable contexts are associated with low IP (or negative) IP enrichment. There is a body of recent literature on this type of analysis that would be worth looking into, e.g. in PLoS
Computational Biology, RNA, etc. there have been a series of such investigations which should be acknowledged and (hopefully) followed. >We realized that the sentence "We observed little increase in predictive power (data not shown) suggesting that the majority of GBMs reside in favorable structural environments" did not explain the point we were trying to make. What we wanted to propose was that in vivo there may be few instances where the GBMs are inaccessible, like in the reporter assay. We extended our genome wide analysis of secondary structure and included our results ( Supplementary Fig. S5 ) and reformulated our conclusions. We did find that GBMs in an unfavorable and potentially inaccessible context are associated with lower IP enrichment however the predicted contribution to GLD-1 binding is limited as compared to the presence of the actual site. This suggests that either the secondary structure predictions do not sufficiently capture the in vivo situation or that in most cases the GBMs are accessible. >All the cuts are arbitrary; we made this clearer in the manuscript. They were mainly motivated by visual inspection (the strong sites were clearly separated from the rest). Modifying the medium to weak boundary had very little influence on the multiplicity figure. We have described within the manuscript how predicted binding score per category was determined. This was computed by summing, in log space, the contribution of all motifs present within a given 3'UTR, and subsequently by averaging the scores of all the transcripts that fall within a given category.
(7) Throughout the manuscript, it is reported that multiple GBMs make additive contributions to the measured binding of GLD-1. However, that's not strictly true because, as the manuscript points out, they are additive in log space which means that the contributions are actually multiplicative.
>We agree with the reviewer and have corrected this throughout the manuscript.
(8) In the last section of the results it is shown that a strong GBM results in an increase in repression. However, how does this show that the strength of the GBM is relevant for translational regulation, vs. transcript stability? Isn't it possible that there are fewer transcripts and that each of them is translated at the same rate?
> In order to make quantification of RNA transcripts possible, we re-created all of our lines (previously multi-copy lines generated by microparticle bombardment) shown in Figure 7 (and also all new strains in Figure 6 ) by mosSCI (which luckily became available in the meantime) to obtain single copy chromosomally integrated lines. This was a major task. We again observe that a strong GBM causes an increase in GFP repression over a weak site. Looking at the RNA levels between these lines both by in situ hybridization (data not shown) and by RT-QPCR ( Figure 7E ) shows that transcript stability is not affected supporting our statement that the effect is translational. Figure 5 . The old Figure 6 has been moved to Supplementary Information and the new Figure 6 contains entirely new data requested by Reviewer 2. The corresponding titled sections in the manuscript are now ëValidation of GBMs in vivo', ëValidation of several novel GLD-1 targets and individual GBMs in vivo' and ëGBMs can induce strength dependent repression'. Figure 7 by gld-1(RNAi) and see a de-repression of GFP expression suggesting that it is indeed GLD-1 binding the GBM and inducing regulation (Supplementary Figure S6) . In gld-1 mutants gonads are tumourous therefore you cannot exclude secondary effects on reporter expression. We therefore reduced the levels of GLD-1 by RNAi and only looked at the gonads that still contained some oocytes.
In addition, I don't see any evidence that GLD-

(10) I would also point out that there is no direct demonstration that GLD-1 binds to the short sequence motifs identified -the evidence is all based on mutation of larger RNAs. I don't see this as a fatal flaw but certainly some of the conclusions might be tempered by this fact, and in my view the title should be modified to reflect only what is solidly and directly supported by the data in the paper.
>The in vitro assay presented now in Figure 4 follows the binding of recombinant GLD-1 to 13nt long RNAs containing the 7nt GBM in the centre. Figure S2 . The IP procedure enriched mainly for germline expressed transcripts with GBMs. We did observe minor enrichment for somatic only transcripts carrying GBMs suggesting that there may be a few false positives at lower IP enrichment values. Additionally one partial explanation for this could be an imperfect assignment of somatic only transcripts determined from microarray comparisons.
2. Fig. 3C shows that there is an excellent correlation between predicted binding score and enrichment in the GLD-1 IP, when comparing IP averages for array-detected mRNAs grouped by binding score. Fig. 3E One possibility is that this may be due to indirect interactions with GLD-1 via mRNP complexes. However we do not think that there is another GLD-1 binding site as in Figure  2B we see no other potential motif that could explain the discrepancy. In addition we analyzed the position of target sites within UTRs to see if this could improve the prediction but the GBM position within a UTR appears to play no role. Figure 3D shows that there is small but significant motif enrichment in the CDS, meaning that a small fraction of sites in the CDS are functional. Taking this into account could increase the correlation in Figure 3E ; however we have no way to identify the small subset of functional CDS sites. Our R squared is 0.64^2=0.4, therefore the model explains 40% of the total variance. We agree that this is far from perfect, but we also would like to point out that other RNA binding studies don't even attempt to show quantitative comparisons between IP enrichment and prediction. They mostly present stratified motif enrichments after introducing arbitrary cutoffs for the IP enrichment. These look good to the eye but hide the true performance of a predictor. Fig. 3E , what would be the R value? > We now included a detailed comparison of GBM and SBE (see Figure for Reviewers 1, Table S2 ). Supplementary table S2 indicates the GBMs that are distinct from the SBE criteria. Figure for reviewers 1 shows the poor correlation between SBE and GBM scores and from this figure it is easy to identify the motifs predicted by only one or both predictions. Furthermore, relative affinities of all GBMs have now been determined in vitro, in an approach similar to that originally used to determine the SBE. These scores correlate well with the GBM scores derived from analysis of IP enrichment ( Figure 4B ). We also performed the suggested analysis (repeat of Figure 3E (Fig. 4) , the authors claim that GBMs, not SBEs, are responsible for regulation. In fact, the critical element identified by the mutation analysis matches both a GBM and an SBE (GBM3/SBE1). Is it possible that both types of elements are functional?? >It is possible that both types of element are functional as there are some motifs such as GBM 3 in glp-1 that are predicted by both the GBMs and SBE criteria (Figure for reviewers 1 ñ left panel) . However there are many additional GBMs not predicted by the SBE criteria, which we have shown can bind GLD-1 in vitro (Figure 4 ) and can mediate repression in vivo (Figure 6 ). Also there are apparently SBEs that are non-functional ñ for example the sequence taatca is present in the cye-1 GBM 1,2,3,4 mutated 3'UTR but this sequence does not bind GLD-1 or mediate repression ( Figure  5 ).
The authors state that "the GBM is distinct from the previously reported SBE", without showing a comparison. The SBE (UACUCA) is in fact a more stringent and shorter GBM??? If SBEs are used instead of GBMs in the analysis presented in
In their analysis of the GLP-1 3' UTR
Sup Fig. 1 lists all mRNAs identified by the array but does not highlight the "948 reproducibly identified mRNAs (page 5)". It would be very helpful if this list were modified to also include gene names and predicted GBM scores (included only in the second list). The list should also highlight the new 948 high confidence GLD-1 targets identified by this study, as well as the previously identified GLD-1 targets.
>We now included public gene names in both datasets S1 and S2. The previously implicated GLD-1 targets are indicated in Supplementary Table S4 including a column showing the IP enrichment from our study. The 948 reproducibly enriched mRNAs with a cut-off of 3 fold (1.58 log2) can be selected from dataset S1. One statement that we would like to push forward in this study is that there exists a GLD-1 binding gradient, no cutoff exists that separates targets from non-targets. Therefore we would prefer to provide the full table with all appropriate information to the community. Fig. 1 list. >We tried to obtain by literature mining protein expression patterns of the 948 mRNAs that were enriched over 3 fold in the GLD-1 IP. 128 of these targets had an antibody available and for 71 of these some data to indicate germline expression pattern existed (Supplementary table S5 ). For 18 insufficient data exists to determine the pattern in the medial germline. 34 have an expression pattern that is compatible with GLD-1 regulation, the protein being either absent or strongly reduced in the medial gonad. The remaining 19 are obviously expressed in the central gonad suggesting that other RBPs might activate their expression, GLD-1 binding is non-productive, or that GLD-1, either alone or in co-operation with other RBPs may regulate some targets at a different stage of RNA metabolism. For the mentioned genes: OMA-2 expression is compatible with GLD-1 regulation (Supplementary  Table S5 ). For EGG-1 there was no antibody available so it is not included in Supplementary Table  S5 . However EGG-1:GFP protein fusions driven either by the endogenous promoter or piepromoter and under the control of the egg-1 3'UTR are only expressed in oocytes and localize to the plasma membrane (Curr Biol. 2005 Dec 20; 15(24) :2222-9).
T23G11.3 was very highly enriched in the IP (13th most enriched). This gene codes for GLD-1 itself, is GLD-1 expected to autoregulate??
>GLD-1 or T23G11.3 is 32nd (dataset 1) and 30th (dataset 2) most enriched. (T23G11.2 is 13th). It is very likely that GLD-1 binds its 3'UTR as we can detect 2 medium and 4 weak GBMs. Auto regulation is an interesting possibility however we don't have further data to support that at this stage.
Referee #3 (Remarks to the Author):
Other comments 1. The RIP is likely to identify RNA targets for GLD-1 coIP RNA binding proteins and some may be germline specific. The fact that elevated amount of RNA targets from the germline versus input were obtained does not necessarily mean they are indeed GLD-1 targets. >We have validated at least a small number of our targets in vivo (Figure 6 ) showing that these are indeed GLD-1 targets. In addition, we included a supplementary figure strengthening our argument by also analyzing GBM occurrences in germline expressed and soma-only expressed transcripts. It shows that the IP mainly enriches for GBM containing germline transcripts. Figures 4 and 7 (Fig. 4) . Many thanks for submitting the revised version of your manuscript EMBOJ-2010-74898R1 to the EMBO Journal. Your study has been seen again by referee 2, who is satisfied with the changes and now supports publication. I also wanted to have the study re-reviewed by referee 1, but unfortunately he/she was unable to spare the time to do this. Since he/she raised concerns outside the expertise of referee 2, I therefore needed to seek additional input on your revision from an expert advisor, whom I asked specifically to comment on the adequacy of your responses to referee 1. His/her comments are appended below as referee 4. As you will see, he/she expresses interest in the study, and finds that you have responded well to most of the criticisms. However, he/she still finds that better description of the difference between GBMs identified here and the previously characterised SBEs needs to be included, and I would ask you to incorporate this. In addition, this advisor also raises a new concern -not mentioned by any of the previous referees -as to appropriate controls for your in vitro validation of GLD1-GBM binding. I do realise that this was not brought up by any of the original referees, and I apologise for the somewhat unconventional process here. However, this does seem to be an important concern -you observe residual binding of GLD1 to GBM-mutated RNAs, suggesting a degree of non-specific binding. Since your analysis is largely concerned with quantitating binding affinities, a proper negative control here -a mutant GLD1 that can not bind RNA -would be very important, at least in the key experiments. I therefore have to ask you to address this concern of referee 4: I hope that this should not be too time-consuming -I would not insist that all experiments are repeated with this negative control, but some demonstration of the degree of non-specific binding, and discussion of how this might affect your interpretations, would be critical here.
The binding assays performed in
I would therefore like to invite you to revise your manuscript according to the comments of referee 4. I note that he/she also mentions the desirability of cross-linking data, but I do not see this as necessary at this stage. I hope that these additional experiments should not prove too timeconsuming, and please don't hesitate to get in touch if you have any further questions or comments regarding this revision.
I look forward to receiving the revised version of your manuscript.
REFEREE REPORTS
Referee #2 (Remarks to the Author):
This revised version addresses all of my concerns. This is a very interesting, landmark paper that should be published as soon as possible.
Referee #4 (Remarks to the Author):
The authors have addressed most of the referee's criticisms and included new information. However, the manuscript is difficult to read and the authors have not made an effort to make the manuscript accessible to the broad readership of the EMBO Journal, which is not a Journal only for computational biologists. For example, the authors explain in great detail how they score 7-mers motifs and Figures 1-3 but they never explain how they measure affinities, so it is not clear whether affinities were measured experimentally unless the reader looks at the Figure legends.
One important criticism raised by the reviewers, that has not been addressed by the authors, is to clearly indicate how GBMs compare to SBEs. On page 10 the authors mention how GBMs differ from SBEs but this paragraph cannot be understood because the SBEs have never been introduced. Therefore I propose that both in Figure 2C and in Figure 3A a consensus SBE motif is shown for comparison.
Also the authors tend to use sentences such as "quantitative ribonomic approach" that sound good but mean nothing and provide no information on the methods used, when in fact what the authors did is to simply perform GLD-1 immunoprecipitations and analyze the associated RNAs. There is also some confusion in the terms used, as it is not always clear whether some statements are supported by experimental data.
Examples:
1. On page 6 the authors write: " ... GLD-1 targets contain substantially longer 3'UTRs when compared to non-targets ( Fig. 2A) suggesting that the majority of regulatory interactions occur via the 3'UTR." This is an extrapolation that is not warranted. The 3' UTR length provides no information about regulation.
2. On page 8 the authors start a paragraph with the sentence: Different 7-mers show differing affinities.." As mentioned above, the authors should introduce this part of the manuscript stating clearly that they have measured affinities experimentally using ribo-oligonucleotides and wild type protein and also explain how these measurements were done. A criticism raised by the reviewers but not addressed by the authors.
3. The validation of GBMs targets in vitro is not very convincing. It seems that GLD1 has general affinity for RNA (which the authors call background) and an increased affinity for RNAs with GBMs. The definition of background is not appropriate; the background levels should be defined with a proper negative control (e.g. a GLD1 protein mutant that cannot bind RNA). Because the protein seems to bind any RNA, there must be a mechanism to achieve a higher degree of specificity in vivo. The authors should comment on this point.
4. Related to point 3, on page 12 the authors write"...an additional mutation of GBM 2 was needed to prevent both GLD-1 binding and translational regulation (Fig. 5C )." This statement is incorrect, binding is still observed suggesting that the protein exhibits some general affinity for RNA. Whether the residual binding represents background binding has not been demonstrated because the authors have not included a proper negative control. Furthermore the statement about translational repression is not warranted because it is not clear how the regulation occurs in this case.
In sum, the manuscript provides important new information regarding GLD1 targets, although in the absence of cross-linking data it is unclear whether GLD1 really binds to the identified targets in vivo. Nevertheless, I think the paper is important in the field of RNA-protein interactions and C. elegans development, but as mentioned before, the authors should make an effort to make the manuscript accessible and also to avoid overstatements and overinterpretation of the results. As the reviewer gives no specific examples, we consulted the advice of our colleague, who publishes genomics papers of relevance to a wide biological audience, to help us identify parts of the manuscript which can be improved. We hope it is more accessible for a broad readership.
For example, the authors explain in great detail how they score 7-mers motifs and Figures 1-3 but they never explain how they measure affinities, so it is not clear whether affinities were measured experimentally unless the reader looks at the Figure legends. Indeed, in Figures 1-3 all values are derived from computational analysis of our GLD-1 RIP-chip enrichment values and not until Figure 4 are relative affinities of the GBMs (identified in Figure 3 ) determined experimentally in vitro using a recombinant GLD-1-STAR domain peptide and short RNAs containing GBMS. We have re-written parts of the main text discussing Figures 1-4 to make this point more clear. Following Figure 4 and in the discussion we interpret/discuss the computationally derived GBM scores (Fig. 3, Table 1 ) as a reflection of GLD-1 binding affinity because: (A). we observe that number of occurrences of the core 6-mers decreased progressively with IP enrichment indicating that our highly reproducible IP enrichment values are a reflection of GLD-1 affinity to mRNAs mediated by enriched motifs (Fig. 2D), (B) . We see a good correlation between relative GBM affinities determined experimentally in vitro and in vivo GBM scores determined via computational analysis of our RIP-chip enrichment values (Fig. 4B, Supplementary  Fig. S1E ). Figure 2C and in Figure 3A a consensus SBE motif is shown for comparison.
One important criticism raised by the reviewers, that has not been addressed by the authors, is to
To address this concern we have now included a Supplementary Figure (Fig. S1 ) which shows consensus SBE and GBM motifs as well as a comparison of GBM and SBE scores. We decided not to include a consensus SBE within Figures 2 and 3 because the GBM was independently identified from unbiased analysis of our IP data.
Also the authors tend to use sentences such as "quantitative ribonomic approach" that sound good but mean nothing and provide no information on the methods used, when in fact what the authors did is to simply perform GLD-1 immunoprecipitations and analyze the associated RNAs. There is also some confusion in the terms used, as it is not always clear whether some statements are supported by experimental data.
We have changed "Quantitative ribonomic" throughout the manuscript as follows,
The quantitative ribonomics analysis predicts that the GBM score reflects GLD-1 binding affinity (Fig. 2D ). Changed to: Computational analysis of the GLD-1 RIP-chip predicts that the GBM score reflects GLD-1 binding affinity (Fig. 2D) .
The change in standard free energy ( G∫) values for all GBMs correlate well (r=0.71) with the scores derived from our quantitative ribonomics approach Changed to: The change in standard free energy ( G∫) values for all GBMs correlate well (r=0.71) with the in vivo GBM scores determined by computational analysis of our RIP-chip enrichment values.
